With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Lazard acted as the exclusive financial advisor to Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

European equity markets may thrive with monetary easing, fiscal expansion, and controlled inflation, despite risks from ...

When Page Campbell's doctor recommended she try an injectable prescription drug called Wegovy to lose weight before ...

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

This commitment marks a critical step in ensuring the sustainability and responsiveness of WHO as it continues its mission to address a growing range of health crises worldwide.

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Lawsuits are piling up as weight-loss drug users report losing their sight: ‘I definitely wouldn’t have taken it’ - Edward ...